JAC Advance Access published online on May 25, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki175
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 77, Brooklyn, NY 11203, USA
* To whom correspondence should be addressed. Objectives: To describe the molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in Brooklyn, NY and assess the in vitro activity of various antibiotic combinations. Methods: Clinical isolates with suspected carbapenem resistance were referred to the central research laboratory from August 2003 to June 2004. Isolates underwent MIC testing, ribotyping, and were analysed for the presence of KPC carbapenemases. Time-kill studies using various antibiotic(s) were performed on selected isolates. Results: Ninety-six isolates were referred from 10 Brooklyn hospitals. All isolates were resistant to the carbapenems with most having MICs >32 mg/L. Few were susceptible to fluoroquinolones and cephalosporins; approximately half were susceptible to aminoglycosides, and 90% to polymyxin B. Two-thirds were susceptible to doxycycline, and all were considered susceptible to the investigational glycylcycline antibiotic tigecycline. Virtually all possessed blaKPC, and over 80% belonged to one ribotype. In time-kill studies involving 16 isolates, tigecycline demonstrated bacteriostatic activity and polymyxin B concentration-dependent bactericidal activity. The combination of polymyxin B at 0.5 x MIC plus rifampicin had synergic activity against 15/16 isolates, including two polymyxin-resistant strains. The combination of polymyxin B plus imipenem had synergic bactericidal activity against 10/16 isolates, but was antagonistic for three isolates. Conclusions: Multiresistant K. pneumoniae with blaKPC are present in multiple hospitals in New York City. The most consistently active agents in vitro were tigecycline and polymyxin B, particularly when the latter was combined with rifampicin. The clinical efficacy of these agents remains to be determined.
Received February 16, 2005
Revised March 31, 2005
Accepted April 26, 2005
Original article
Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents
David Landman, E-mail: dlandman{at}downstate.edu
Abstract 
-lactamases; imipenem; tigecycline.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. A. Mendes, J. A Cordeiro, and E. A Burdmann Prevalence and Risk Factors for Acute Kidney Injury Associated with Parenteral Polymyxin B Use Ann. Pharmacother., December 1, 2009; 43(12): 1948 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Endimiani, J. M. DePasquale, S. Forero, F. Perez, A. M. Hujer, D. Roberts-Pollack, P. D. Fiorella, N. Pickens, B. Kitchel, A. E. Casiano-Colon, et al. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system J. Antimicrob. Chemother., November 1, 2009; 64(5): 1102 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Baraniak, R. Izdebski, M. Herda, J. Fiett, W. Hryniewicz, M. Gniadkowski, I. Kern-Zdanowicz, K. Filczak, and U. Lopaciuk Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4565 - 4567. [Full Text] [PDF]
|
|
|
|
|
|
A. Endimiani, K. M. Hujer, A. M. Hujer, E. S. Armstrong, Y. Choudhary, J. B. Aggen, and R. A. Bonomo ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae Isolates Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4504 - 4507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Has the era of untreatable infections arrived? J. Antimicrob. Chemother., September 1, 2009; 64(suppl_1): i29 - i36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Endimiani, Y. Choudhary, and R. A. Bonomo In Vitro Activity of NXL104 in Combination with {beta}-Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3599 - 3601. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Toye, S. Krajden, M. Fuksa, D. E. Low, and D. R. Pillai Carbapenem resistance in Canada Can. Med. Assoc. J., June 9, 2009; 180(12): 1225 - 1226. [Full Text] [PDF]
|
|
|
|
|
|
T. D. Gootz, M. K. Lescoe, F. Dib-Hajj, B. A. Dougherty, W. He, P. Della-Latta, and R. C. Huard Genetic Organization of Transposase Regions Surrounding blaKPC Carbapenemase Genes on Plasmids from Klebsiella Strains Isolated in a New York City Hospital Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1998 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Endimiani, A. M. Hujer, F. Perez, C. R. Bethel, K. M. Hujer, J. Kroeger, M. Oethinger, D. L. Paterson, M. D. Adams, M. R. Jacobs, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA J. Antimicrob. Chemother., March 1, 2009; 63(3): 427 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marschall, R. J. Tibbetts, W. M. Dunne Jr., J. G. Frye, V. J. Fraser, and D. K. Warren Presence of the KPC Carbapenemase Gene in Enterobacteriaceae Causing Bacteremia and Its Correlation with In Vitro Carbapenem Susceptibility J. Clin. Microbiol., January 1, 2009; 47(1): 239 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kelesidis, D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies J. Antimicrob. Chemother., November 1, 2008; 62(5): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tibbetts, J. G. Frye, J. Marschall, D. Warren, and W. Dunne Detection of KPC-2 in a Clinical Isolate of Proteus mirabilis and First Reported Description of Carbapenemase Resistance Caused by a KPC {beta}-Lactamase in P. mirabilis J. Clin. Microbiol., September 1, 2008; 46(9): 3080 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Chmelnitsky, S. Navon-Venezia, J. Strahilevitz, and Y. Carmeli Plasmid-Mediated qnrB2 and Carbapenemase Gene blaKPC-2 Carried on the Same Plasmid in Carbapenem-Resistant Ciprofloxacin-Susceptible Enterobacter cloacae Isolates Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2962 - 2965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Landman, C. Georgescu, D. A. Martin, and J. Quale Polymyxins Revisited Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Rasheed, J. W. Biddle, K. F. Anderson, L. Washer, C. Chenoweth, J. Perrin, D. W. Newton, and J. B. Patel Detection of the Klebsiella pneumoniae Carbapenemase Type 2 Carbapenem-Hydrolyzing Enzyme in Clinical Isolates of Citrobacter freundii and K. oxytoca Carrying a Common Plasmid J. Clin. Microbiol., June 1, 2008; 46(6): 2066 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Marchaim, S. Navon-Venezia, M. J. Schwaber, and Y. Carmeli Isolation of Imipenem-Resistant Enterobacter Species: Emergence of KPC-2 Carbapenemase, Molecular Characterization, Epidemiology, and Outcomes Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1413 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Schwaber, S. Klarfeld-Lidji, S. Navon-Venezia, D. Schwartz, A. Leavitt, and Y. Carmeli Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1028 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pliatsika, Z. Afkou, E. Protonotariou, and D. Sofianou In vitro activity of tigecycline against metallo-{beta}-lactamase-producing Enterobacteriaceae J. Antimicrob. Chemother., December 1, 2007; 60(6): 1406 - 1407. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert, D. E. Low, F. Rossi, X. Zhang, C. Wattal, and M. J. Dowzicky Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline J. Antimicrob. Chemother., November 1, 2007; 60(5): 1018 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Falagas, P. I. Rafailidis, D. Kofteridis, S. Virtzili, F. C. Chelvatzoglou, V. Papaioannou, S. Maraki, G. Samonis, and A. Michalopoulos Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study J. Antimicrob. Chemother., November 1, 2007; 60(5): 1124 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Walther-Rasmussen and N. Hoiby Class A carbapenemases J. Antimicrob. Chemother., September 1, 2007; 60(3): 470 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Leavitt, S. Navon-Venezia, I. Chmelnitsky, M. J. Schwaber, and Y. Carmeli Emergence of KPC-2 and KPC-3 in Carbapenem-Resistant Klebsiella pneumoniae Strains in an Israeli Hospital Antimicrob. Agents Chemother., August 1, 2007; 51(8): 3026 - 3029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Queenan and K. Bush Carbapenemases: the Versatile {beta}-Lactamases Clin. Microbiol. Rev., July 1, 2007; 20(3): 440 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Landman, S. Bratu, S. Kochar, M. Panwar, M. Trehan, M. Doymaz, and J. Quale Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY J. Antimicrob. Chemother., July 1, 2007; 60(1): 78 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Rodloff, E. J. C. Goldstein, and A. Torres Two decades of imipenem therapy J. Antimicrob. Chemother., November 1, 2006; 58(5): 916 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Kaczmarek, F. Dib-Hajj, W. Shang, and T. D. Gootz High-Level Carbapenem Resistance in a Klebsiella pneumoniae Clinical Isolate Is Due to the Combination of blaACT-1 {beta}-Lactamase Production, Porin OmpK35/36 Insertional Inactivation, and Down-Regulation of the Phosphate Transport Porin PhoE. Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3396 - 3406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Waites, L. B. Duffy, and M. J. Dowzicky Antimicrobial Susceptibility among Pathogens Collected from Hospitalized Patients in the United States and In Vitro Activity of Tigecycline, a New Glycylcycline Antimicrobial. Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3479 - 3484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Navon-Venezia, I. Chmelnitsky, A. Leavitt, M. J. Schwaber, D. Schwartz, and Y. Carmeli Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant Escherichia coli Clones in Israel. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3098 - 3101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Moland, N. D. Hanson, J. A. Black, A. Hossain, W. Song, and K. S. Thomson Prevalence of Newer {beta}-Lactamases in Gram-Negative Clinical Isolates Collected in the United States from 2001 to 2002. J. Clin. Microbiol., September 1, 2006; 44(9): 3318 - 3324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-I. Morosini, M. Garcia-Castillo, T. M. Coque, A. Valverde, A. Novais, E. Loza, F. Baquero, and R. Canton Antibiotic Coresistance in Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of Tigecycline. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2695 - 2699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Burgess and C. R. Frei Comparison of {beta}-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics J. Antimicrob. Chemother., November 1, 2005; 56(5): 893 - 898. [Abstract] [Full Text] [PDF]
|
|